Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: A series of 52 patients

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 623-630

  Akhavan Sigari, Reza ^a   Gaab, Michael Robert ^b   Rohde, Veit ^a   Abili, Mehdi ^c   Ostertag, Helmut ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NORDSTADT HOSPITAL   (Germany)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C MET; EGFR; PDGFR ; Spinal chordoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CERVICAL SPINE; CHORDOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SACRAL SPINAL CORD; SCORING SYSTEM; SPINAL CHORDOMA; THORACIC SPINE; BIOSYNTHESIS; C-MET; COHORT ANALYSIS; EGFR; ENZYMOLOGY; MIDDLE AGED; PATHOLOGY; PDGFR-Α; SPINAL CORD TUMOR; VERY ELDERLY; YOUNG ADULT;

C-MET; EGFR; PDGFR-Α; SPINAL CHORDOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHORDOMA; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SPINAL CORD NEOPLASMS; YOUNG ADULT;

EID: 84897101393     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. al-Mefty O and Borba LA: Skull base chordomas: a management challenge. J Neurosurg 86(2): 182-189, 1997.
2. Mendenhall WM, Mendenhall CM, Lewis SB, Villaret DB and Mendenhall NP: Skull base chordoma. Head Neck 27(2): 159-165, 2005.
3. Tzortzidis F, Elahi F, Wright D, Natarajan SK and Sekhar LN: Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59(2): 230-237, 2006.
4. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM and Baker LH: Chordoma: the nonsarcoma primary bone tumor. The oncologist 12(1): 1344-1350, 2007.
5. Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A and Sasaki CT: Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch. Otolaryngol. Head Neck Surg 131(8): 707-711, 2005.
6. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA and Reiss M: Tissue microarray: a new technology for amplification of tissue resources. Cancer J. Sudbury Mass 7(1): 24-31, 2001.
7. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A and Baselga J: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol Off J Am Soc Clin Oncol 22(1): 175-184, 2004.
8. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology and College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. Off J Am Soc Clin Oncol 25(1): 118-145, 2007.
9. O'Connell JX, Renard LG, Liebsch NJ, Efird JT, Munzenrider JE and Rosenberg AE: Base of skull chordoma. A correlative study of histologic and clinical features of 62 cases. Cancer 74(8): 2261-2267, 1994.
10. Volpe R and Mazabraud A: A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm). Am J Surg Pathol 7(2): 161-170, 1983.
11. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W and Meis-Kindblom JM: Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88( 9): 2122-2134, 2000.
12. Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M and Roessner A: Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions. Am J Clin Pathol 124(2): 288-294, 2005.
13. Naka T, Boltze C, Kuester D, Schulz T-O, Samii A, Herold C, Ostertag H and Roessner A: Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol 122(6): 926-930, 2004.
14. Naka T, Boltze C, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D and Roessner A: Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer 98(9): 1934-1941, 2003.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA. Cancer J Clin 57(1): 43-66, 2007.
16. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jäkel O, Karger C, Kraft G, Wannenmacher M and Debus J: Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys 58(2): 631-640, 2004.
17. Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, Lomax AJ and Goitein G: Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys 63(2): 401-409, 2005.
18. Fleming GF, Heimann PS, Stephens JK, Simon MA, Ferguson MK, Benjamin RS and Samuels BL: Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 72(3): 714-718, 1993.
19. Ptaszyński K, Szumera-Ciećkiewicz A, Owczarek J, Mrozkowiak A, Pekul M, Barańska J and Rutkowski P: Epidermal growth factor receptor (EGFR) status in chordoma. Pol J Pathol Off J Pol Soc Pathol 60(2): 81-87, 2009.
20. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA and Pilotti S: Imatinib mesylate in chordoma. Cancer 101(9): 2086-2097, 2004.
21. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S and Casali PG: Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol Off J Eur Soc Med Oncol 20(11): 1886-1894, 2009.
22. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG and Pilotti S: Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin. Cancer Res Off J Am Assoc Cancer Res 12(23): 6920-6928, 2006.
23. Hof H, Welzel T and Debus J: Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 29(12): 572-574, 2006.
24. Lindén O, Stenberg L and Kjellén E: Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol Stockh Swed 48(1): S.158-159, 2009.
25. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TRW, Bacsi K, Kindblom L-G, Athanasou N, Amary MF, Hogendoorn PCW, Tirabosco R and Flanagan AM: The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol 223(3): 336-346, 2011.
26. Fasig JH, Dupont WD, LaFleur BJ, Olson SJ and Cates JMM: Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol 34(1): 95-104, 2008.
27. Belfiore A, Gangemi P, Costantino A, Russo G, Santonocito GM, Ippolito O, Di Renzo MF, Comoglio P, Fiumara A and Vigneri R: Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab 82(7): 2322-2328, 1997.
28. Terada T, Nakanuma Y and Sirica AE: Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 29(2): 175-180, 1998.
29. Aishima S-I, Taguchi K-I, Sugimachi K, Shimada M, Sugimachi K and Tsuneyoshi M: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40(3): 269-278, 2002.
30. Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J and Davaris PS: c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 36(4): 313-325, 2000.
31. Naka T, Kuester D, Boltze C, Scheil-Bertram S, Samii A, Herold C, Ostertag H, Krueger S and Roessner A: Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer 112(1): 104-110, 2008.
32. Comoglio PM: Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS 65: 131-165, 1993.
33. Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG and Comoglio PM: The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. J Int Cancer 49(3): 323-328, 1991.
34. Negri T, Casieri P, Miselli F, Orsenigo M, Piacenza C, Stacchiotti S, Bidoli P, Casali PG, Pierotti MA, Tamborini E and Pilotti S: Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. Br J Cancer 96(1): 180-181, 2007.